Abstracts tagged "Disease Activity"

Abstract Number: 2279 • 2013 ACR/ARHP Annual Meeting
Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
E. Gvozdenovic¹, R. Wolterbeek², C.F. Allaart¹, Claiton Brenol³, Arvind Chopra⁴, Maxime Dougados⁵, Paul Emery⁶, D. van der Heijde⁷, T.W.J. Huizinga¹, Jonathan Kay⁸, Emilio Martín Mola⁹, Robert J. Moots¹⁰, José A. P. Da Silva¹¹, Josef S. Smolen¹², Douglas J. Veale¹³ and R. Landewe¹⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Biostatistics, Leiden University Medical Center, Leiden, Netherlands, ³Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁴Rheumatology, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁹Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, ¹⁰Clinical Sciences Centre, University of Liverpool, Liverpool, United Kingdom, ¹¹Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹²Medical University of Vienna, Vienna, Austria, ¹³Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ¹⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Edward Keystone¹, MC Genovese², Peter Taylor³, Baojin Zhu⁴, Scott D. Beattie⁴, Stephanie de Bono⁴, Terence Rooney⁴, Douglas E. Schlichting⁴ and William Macias⁴, ¹University of Toronto, Toronto, ON, Canada, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Yomei Shaw¹, Daisy Bang², Heather Eng³, Stephen R. Wisniewski⁴, Mark S. Roberts¹ and Marc C. Levesque⁵, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…
Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…
Abstract Number: 2280 • 2013 ACR/ARHP Annual Meeting
Stiffness From The Perspective Of People Living With Rheumatoid Arthritis
Ana-Maria Orbai¹, Katherine Clegg-Smith², Susan J. Bartlett³, Elaine De Leon⁴, Michelle Jones⁵ and Clifton O. Bingham III¹, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Health Behavior and Society, Johns Hopkins University School of Public Health, Baltimore, MD, ³Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Stiffness was included in the 1961 and 1987 Rheumatoid Arthritis (RA) classification criteria and continues to be commonly queried in clinical care. Its relative…
Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra^® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Wanying Li¹, DJ Haney¹, Guy Cavet¹, Thomas W. Huizinga², Eric H. Sasso¹ and A. H. M. van der Helm-van Mil³, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
Abstract Number: 1357 • 2013 ACR/ARHP Annual Meeting
Coping Style Is An Independent Predictor For Disease Activity At Three Months In Early Arthritis Patients Initiating Therapy With Disease Modifying Anti-Rheumatic Drugs
T. Martijn Kuijper¹, Hong Xiong², A.E.a.M. Weel³, A.H. Gerards⁴, Jendé van Zeben⁵, P.H.P. de Jong⁶, Ilja Tchetverikov⁷, P.B.J. de Sonnaville⁸, M.V. Krugten⁹, B.A. Grillet¹⁰, Jolanda J. Luime² and Johanna M.W. Hazes¹¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁸Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, ¹⁰Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: To explore the effect of psychosocial factors on the Disease Activity Score (DAS) and its components in early arthritis patients three months after initiating…
Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Yoon-Kyoung Sung^1,2, Kazuki Yoshida^2,3, Femke H.M. Prince^2,4, Michelle A. Frits², Jung-Yoon Choe⁵, Won Tae Chung⁶, Jisoo Lee⁷, Eun-Mi Koh⁸, Dae-Hyun Yoo⁹, Simon M. Helfgott², Nancy A. Shadick¹⁰, Michael E. Weinblatt¹¹, Sang-Cheol Bae¹ and Daniel H. Solomon², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁴Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁷Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ¹¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
Abstract Number: 380 • 2013 ACR/ARHP Annual Meeting
Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease
Ryosuke Hanaoka^1,2, Kazuhiro Kurasawa³, Ayae Tanaka⁴ and Harutsugu Okada⁵, ¹Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Japan, ²Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Tochigi, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan, ⁵Clinical Immunology, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects not only joints but also many organs. RA causes vascular damages to contribute to…
Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting
Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis
Michal Tomcik¹, Lucie Andres Cerezo¹, Simona Skacelova², Martin Komarc³, Radim Becvar¹, Mariam Grigorian⁴, Joerg HW Distler⁵ and Ladislav Senolt¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, ⁵Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…
Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting
Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry
William G. Bensen¹, Algis V Jovaisas², J. Carter Thorne³, Philip Baer⁴, Majed M. Khraishi⁵, Sanjay Dixit⁶, Denis Choquette⁷, Michael Starr⁸, Isabelle Fortin⁹, Dalton E. Sholter¹⁰, Emmanouil Rampakakis^11,12, John S. Sampalis^11,12, Francois Nantel¹³, Allen J. Lehman¹⁴, May Shawi¹⁵ and Susan M. Otawa¹⁴, ¹Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸Montreal General Hospital, Montreal, QC, Canada, ⁹Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹⁰Rheumatology Associates, Edmonton, AB, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
Abstract Number: 1779 • 2013 ACR/ARHP Annual Meeting
A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis
Li Alemo Munters^1,2, Ingela M. Loell³, Joan Raouf⁴, Maryam Dastmalchi³, Eva Lindroos⁵, Christina Ottosson⁶, Yi-Wen Chen⁷, Annemarie F van Delden⁸, Mona Esbjörnsson⁹, Marina Korotkova¹⁰, Helene Alexanderson¹¹, Kanneboyina Nagaraju¹² and Ingrid E. Lundberg¹³, ¹Department of Medicine, Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Physiotherapy, Rheumatology Unit, Karolinska University Hospital in Solna, Stockholm, Sweden, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁷Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁸Department of Medicine,, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁹Department of Physiology, Karolinska Institutet, Huddinge, Sweden, ¹⁰Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ¹¹Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, ¹²Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG)…
Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Eimear Savage¹, David McCormick¹, Stephen McDonald¹, Michael Stevenson², Owen Moore³ and Andrew Cairns⁴, ¹Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, ²Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, ³Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁴Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].